Welcome to our dedicated page for CapsoVision news (Ticker: CV), a resource for investors and traders seeking the latest updates and insights on CapsoVision stock.
CapsoVision, Inc. develops and markets capsule endoscopy technology for gastrointestinal imaging. The company’s flagship product, CapsoCam Plus®, is a wire-free panoramic capsule endoscope for small-bowel visualization with cloud-based or direct capsule video retrieval. News about CV commonly covers commercial adoption, quarterly financial results, account growth, product development and the company’s Nasdaq-listed public-company activity.
Recurring updates also include FDA submissions for AI-assisted capsule endoscopy tools, development work on CapsoCam Colon™, CMOS sensor development with Canon, private placement financing, investor conference participation and corporate governance or finance leadership changes.
Visteon (NASDAQ:VC) reported second quarter 2026 net sales of $960 million, slightly below $969 million a year earlier, with 4% growth-over-market driven by launch ramps and regional execution. Net income attributable to Visteon was $49 million, or $1.80 diluted EPS. Adjusted EBITDA was $116 million, a 12.1% margin, supported by customer commercial recoveries and cost discipline, partly offset by higher supplier costs and continued engineering investments.
Operating cash flow for the quarter was $37 million, with free cash flow of $12 million. For the first six months of 2026, operating cash flow totaled $43 million and adjusted free cash flow was an outflow of $3 million. Visteon ended the quarter with $650 million in cash, $299 million of debt and a net cash position of $351 million. The company booked approximately $2.0 billion in new business and launched 24 new products across 11 customers.
Visteon also announced a $200 million accelerated share repurchase under its existing $800 million authorization, expected to complete early in the fourth quarter of 2026, aligning with its capital allocation focus on shareholder returns and growth investment.
CapsoVision (Nasdaq: CV) appointed gastroenterology specialist David S. Shields, M.D. to its Board of Directors, effective July 1, 2026, succeeding Joanne C. Imperial, M.D., who will remain as an independent clinical consultant.
Dr. Shields brings over 40 years of gastroenterology experience, nearly two decades with capsule endoscopy, and a long advisory role to CapsoVision as the company advances its AI-enabled capsule endoscopy platform, including CapsoCam Plus®, CapsoCam Colon™ and future clinical programs.
CapsoVision (NASDAQ: CV) reported first quarter 2026 revenue of $2.8 million, stable year over year. Gross profit was $1.3 million with a 48% gross margin, impacted by U.S. trade policies and tariffs.
Operating expenses rose to $8.4 million, driven by CMOS sensor development with Canon and clinical trials. Cash and equivalents totaled $17.9 million following a $14 million private placement. The company highlighted growing CapsoCam Plus® usage, key GI network renewals, upcoming FDA review of its AI-assisted reading feature, and progress on colon and pancreatic cancer programs.
CapsoVision (NASDAQ: CV) will release first quarter 2026 financial results on May 14, 2026 after market close. A conference call and live webcast are scheduled for 1:30 pm PT / 4:30 pm ET that day to discuss results and provide a corporate update.
Investors can dial (800) 715-9871 or (646) 307-1963 with conference ID 5439091. The live and archived webcast will be available on the Events page in the Investor Relations section of CapsoVision’s website.
CapsoVision (NASDAQ: CV) reported fourth-quarter revenue of $3.9 million (+13% YoY) and full-year 2025 revenue of $13.6 million (+15% YoY). Gross profit for 2025 was $7.2 million with a 53% full-year gross margin. Operating expenses rose to $32.7 million, up $6.4 million year-over-year. Cash and cash equivalents were $10.1 million at year-end. The company submitted a 510(k) for an AI-assisted module for CapsoCam Plus and completed a $14 million private placement on March 16, 2026, after an IPO in July 2025.
CapsoVision (NASDAQ: CV) closed a $14.0 million private placement on March 16, 2026, selling 2,867,089 shares at $4.883 per share (5% discount to the March 16 close).
Net proceeds will fund sales, R&D, G&A and working capital. Preliminary Q4 revenue was $3.9M, full-year 2025 revenue $13.6M, and cash and investments were approximately $10.1M as of December 31, 2025. Registration rights require a resale registration statement within 90 days; full audited results and a webcast are scheduled for March 26, 2026.
CapsoVision (NASDAQ: CV) will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after market close.
The company will host a conference call and live webcast on March 26, 2026 at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Dial-in numbers: (800) 715-9871 (US) or (646) 307-1963 (international); conference ID 2525025. The webcast replay will be available for one year via the Events page in investor relations; registration required to access the replay.
CapsoVision (NASDAQ: CV) will present at the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Management will host a fireside chat and hold 1x1 investor meetings at 10:30–10:55 am PT.
The fireside chat will be webcast live and archived on the company Events page for one year; investors can request one-on-one meetings via their Roth representative or Investors@CapsoVision.com.
CapsoVision (NASDAQ: CV) submitted a 510(k) to the U.S. Food and Drug Administration on Dec. 29, 2025 for an AI-assisted reading module for its CapsoCam Plus capsule endoscopy system.
The module is intended to improve detection of clinically significant small-bowel pathology and reduce clinician review time. The company said it plans to begin U.S. commercialization after FDA clearance. CapsoCam Plus is indicated for visualization of the small bowel mucosa in adults and children aged two years and older.
CapsoVision highlighted in-house AI capabilities, a growing image data set for model training, and a fully cloud-based architecture intended to remove on-site servers and reduce IT maintenance.
CapsoVision (NASDAQ: CV) announced that senior management will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025 in New York City.
Attending executives include Johnny Wang, President and CEO; David Garcia, SVP Finance; and Doug Atkinson, SVP Global Sales. Investors seeking a one-on-one meeting are asked to contact their Benchmark representative or email Investors@CapsoVision.com.